Shortly after closing the NMR business in late 2014 Agilent announced it would recombine its Life Science group and Chemical analysis group into one business, to be called LSAG. The reason was better focus on customers and optimization (/cost savings). However, the restructure involved nearly exclusively the layoff and redundancy of the entire old Life science management and portions of the LS sales team world wide. Internally it has been viewed as many as creating a severe gap in the knowledge of the LS business within Agilent. Internally, it was also viewed as MM giving payback after winning the long internal battle for the replacement of BS as CEO. In any case the restructure and its poor execution has created significant employee moral issues. The layoffs happened in early Q2 business, so it will be interesting to see the impact on Q2 results (May). The company is much leaner now, but has lost so much experience and probably some of its loyal LS customers. It will also be interesting to see the longer term sales impact on the new customer philosophy that the new senior management team (all old CA no LS managers) bring to its life science customers. The focus on the LS business has certainly been diminished
1 reply
I am with Life Science Group and can confirm all that Anonymous90387 noted above